Every 10-Q that Soleno Therapeutics, Inc. (SLNO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLNO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLNO filings page.
Soleno Therapeutics reported a profitable quarter as VYKAT XR commercialization scaled up and the company agreed to a cash buyout. For the three months ended March 31, 2026, product revenue reached $94.6 million, all from VYKAT XR sales, driving net income of $31.4 million compared with a $43.8 million loss a year earlier.
Total operating expenses were $63.3 million, mainly from selling, general and administrative costs of $50.4 million tied to commercial launch, while research and development fell to $11.3 million. The company ended the quarter with $133.0 million in cash and cash equivalents, $396.0 million in marketable securities and $50.0 million of long-term debt outstanding under its Oxford loan.
On April 5, 2026, Soleno entered into a Merger Agreement with Neurocrine Biosciences under which Neurocrine commenced a cash tender offer at $53.00 per share. If completed, Soleno will become a wholly owned subsidiary of Neurocrine. The company also achieved both commercial milestones under its Essentialis acquisition, triggering earnout payments, and believes current liquidity and cash flows will fund operations for at least the next twelve months.
Soleno Therapeutics (SLNO) reported its first profitable quarter as a commercial company. For Q3 2025, product revenue was $66.0 million, driving operating income of $22.1 million and net income of $26.0 million. Year-to-date, product revenue reached $98.7 million. The company began recognizing sales after the FDA approved VYKAT XR in March 2025 to treat hyperphagia in Prader-Willi syndrome and first prescriptions shipped in April.
Liquidity strengthened significantly: cash and cash equivalents were $246.7 million and marketable securities were $309.4 million at September 30, 2025. In July, Soleno completed an underwritten offering of 2,705,882 shares at $85.00 per share for gross proceeds of $230.0 million (approximately $14.3 million in offering costs). Long-term debt outstanding was $50.0 million under the Oxford facility, with additional tranches available subject to terms. Shares outstanding were 53,710,025 as of October 31, 2025.